Drug intelligence / Profile preview

SYP-0704A

Development stage: Unknown
Lead developer: Samyang Biopharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

SYP-0704A is an investigational formulation of docetaxel evaluated in a Phase 1 pharmacokinetic study comparing it with Taxotere in patients with advanced solid tumors. Docetaxel is a taxane chemotherapeutic that stabilizes microtubules, preventing depolymerization and thereby inhibiting mitosis in rapidly dividing cancer cells. The study sponsor was Samyang Biopharmaceuticals Corporation, suggesting SYP-0704A is a Samyang-developed docetaxel product intended to assess bio/pharmacokinetic similarity or improved formulation characteristics relative to Taxotere.[7][4][3]

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SYP-0704A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-0704A.

Explore the full profile